Autologous stem cell transplantation in patients with mantle cell lymphoma.

Abstract:

:High-dose therapy followed by autologous stem cell transplantation (ASCT) has been considered a potential treatment approach in order to improve the poor prognosis in mantle cell lymphoma (MCL), but its role has not yet been clearly established. We analyzed retrospectively the outcome and prognostic factors in 48 consecutive patients with MCL scheduled for ASCT in five transplant centers. In 14 patients (29%), a sufficient amount of stem cells could not be collected. Mobilization failure was associated with female sex, blastoid cytology, and low hemoglobin level. Altogether 35 patients underwent ASCT, 24 patients as part of the first-line treatment and 11 patients later. After transplantation 28 patients (80%) remained in or achieved remission. Two patients died of transplant-related complications. During the median follow-up time of 38 months, nine patients have relapsed. The median event-free survival (EFS) was 39 months. Age over 60 years and elevated C-reactive protein level at diagnosis were associated with poorer outcome after transelantation. ASCT is an effective treatment in MCL with a high response rate and a longer survival than seen in conventionally treated patients. However, no plateau was seen in the EFS curve after ASCT. Whether cure Can be achieved in a proportion of patients with ASCT is currently unknown and should be studied in larger patient series with a longer follow-up.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Oinonen R,Jantunen E,Itälä M,Lehtinen T,Kuittinen O,Franssila K,Wiklund T,Elonen E

doi

10.1080/10428190290026286

keywords:

subject

Has Abstract

pub_date

2002-06-01 00:00:00

pages

1229-37

issue

6

eissn

1042-8194

issn

1029-2403

journal_volume

43

pub_type

杂志文章,meta分析
  • Lack of CD54 expression and mutation of p53 gene relate to the prognosis of childhood Burkitt's lymphoma.

    abstract::Expression of the intercellular adhesion molecule-1 (CD54) as well as the mutations of p53 gene were studied in childhood Burkitt's lymphoma (BL). Expression of CD54 was identified in 6 of 15 fresh BL cases. Mutations of p53 gene, analyzed by polymerase chain reaction-single stranded chain polymorphism followed by seq...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199609093443

    authors: Kaneko H,Sugita K,Kiyokawa N,Iizuka K,Takada K,Saito M,Yoshimoto K,Itakura M,Kokai Y,Fujimoto J

    更新日期:1996-05-01 00:00:00

  • The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study).

    abstract::Indolent lymphomas primarily involving the skeleton (iPBL) represent < 1% of all primary bone lymphomas. The management and prognosis have not been previously described. Patients with primary and secondary iPBL were selected from an international database of 499 patients with a histopathological diagnosis of non-Hodgk...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2013.853298

    authors: Govi S,Christie D,Mappa S,Marturano E,Bruno-Ventre M,Messina C,Medina EA,Porter D,Radford J,Heo DS,Park Y,Pro B,Jayamohan J,Pavlakis N,Zucca E,Gospodarowicz M,Ferreri AJ,International Extranodal Lymphoma Study Group.

    更新日期:2014-08-01 00:00:00

  • Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients.

    abstract::We retrospectively analyzed immunosuppression status in 287 newly diagnosed multiple myeloma (MM) patients and assessed the prognostic value of immunoparesis on survival. Deep immunoparesis was defined that one of uninvolved immunoglobulins was below 50% the lower limit of normal ranges, partial immunoparesis was defi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1855345

    authors: Geng C,Yang G,Wang H,Wu Y,Leng Y,Zhou H,Zhang Z,Jian Y,Chen W

    更新日期:2020-12-04 00:00:00

  • Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.

    abstract::The clinical significance and mechanisms of TET2 are not well defined in myeloid malignancies. We detected TET2 mutations and assayed its catalyzing conversion product 5-hydroxymethylcytosine (5-hmC) in 61 Chinese patients with MDS. Ten patients were identified to have TET2 mutations (16.4%). 5-hmC levels in patients ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.778408

    authors: Liu X,Zhang G,Yi Y,Xiao L,Pei M,Liu S,Luo Y,Zhong H,Xu Y,Zheng W,Shen J

    更新日期:2013-11-01 00:00:00

  • Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis.

    abstract::We performed a registry-based analysis of 311 AML patients treated with decitabine in a standard of care setting to assess response and survival data with a distinct focus on the impact of the TP53 mutation status. Median age was 73 years. 172 patients received decitabine first-line and 139 in r/r disease. The ORR (wh...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1864354

    authors: Middeke JM,Teipel R,Röllig C,Stasik S,Zebisch A,Sill H,Kramer M,Scholl S,Hochhaus A,Jost E,Brümmendorf TH,Naumann R,Steffen B,Serve H,Altmann H,Kunzmann V,Einsele H,Parmentier S,Schaich M,Burchert A,Neubauer A,S

    更新日期:2021-01-05 00:00:00

  • Response to hyperfractionated accelerated radiotherapy in chemotherapy-refractory non-Hodgkin lymphoma.

    abstract::Patients with chemotherapy-refractory non-Hodgkin lymphoma (NHL) have a poor prognosis with a median overall survival (OS) of only 10 months. To investigate the role of radiotherapy (RT) in such patients, we conducted a retrospective review of 17 patients with biopsy-proven refractory NHL who received hyperfractionate...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1719096

    authors: Kim DW,Lee G,Lee H,Mahal AR,Lam MB,Ng AK

    更新日期:2020-06-01 00:00:00

  • Neutropenia and leukemia development: genetic risk factors and prognosis.

    abstract::Neutropenia is known as a clinical consequence in various genetic disorders and other neutropenia-inducing mutations (NIM) nonmalignant diseases. Leukemia development is now a major concern about the mortality of patients with congenital neutropenia. We searched the PubMed database and Google Scholar engine using Engl...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2019.1630622

    authors: Shahrabi S,Maleknia M,Tavakolifar Y,D Zayeri Z,Saki N

    更新日期:2019-12-01 00:00:00

  • Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1.

    abstract::HMGB1 is a high mobility group protein that can act either as a DNA binding protein or extracellularly as a cytokine-like danger signal. Extracellular HMGB1, either actively secreted or passively released by necrotic cells, is linked to inflammation and cancer. Herein, the results of a study to quantify the expression...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190802064909

    authors: Meyer A,Staratschek-Jox A,Springwald A,Wenk H,Wolf J,Wickenhauser C,Bullerdiek J

    更新日期:2008-06-01 00:00:00

  • Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493).

    abstract::The purpose of this study was to determine the activity of topotecan given by 21-day continuous infusion in patients previously treated with one prior therapy for a diffuse large-cell lymphoma or immunoblastic lymphoma. Patients with appropriate histology and measurable disease who had been treated with one prior chem...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.643406

    authors: Wiernik PH,Li H,Weller E,Hochster HS,Horning SJ,Nazeer T,Gordon LI,Habermann TM,Minniti CJ Jr,Shapiro GR,Cassileth PA

    更新日期:2012-06-01 00:00:00

  • The potential evasion of immune surveillance in mucosa associated lymphoid tissue lymphoma by DcR2-mediated up-regulation of nuclear factor-κB.

    abstract::This study investigated expression profiles of tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) pathway components and mechanisms underlying TRAIL-induced apoptosis in mucosa associated lymphoid tissue (MALT) lymphoma. Genetic aberrations including translocations and trisomies were assessed by rev...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.953149

    authors: Anees M,Horak P,Schiefer AI,Vaňhara P,El-Gazzar A,Perco P,Kiesewetter B,Müllauer L,Streubel B,Raderer M,Krainer M

    更新日期:2015-05-01 00:00:00

  • Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation.

    abstract::The ubiquitin-proteasome-dependent proteolytic system has been reported to regulate apoptotic cell death in many experimental cell models. We recently found that B-CLL (chronic lymphocytic leukemia) lymphocytes are hypersensitive to apoptotic death activation through specific inhibition of proteasome function by lacta...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190009059268

    authors: Masdehors P,Merle-Béral H,Magdelénat H,Delic J

    更新日期:2000-08-01 00:00:00

  • Clinical significance of pre- and 1-year post-transplant serum ferritin among adult transplant recipients.

    abstract::To clarify the significance of post-transplant serum ferritin (SF), we retrospectively assessed pre- and post-transplant SF. Among 256 patients undergoing allogeneic stem cell transplant (SCT) for hematologic malignancies between 2000 and 2011, those who had relapsed within 1 year were excluded, and 110 patients survi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.842981

    authors: Tachibana T,Tanaka M,Numata A,Matsumoto K,Tomita N,Fujimaki K,Taguchi J,Sakai R,Fujita H,Fujisawa S,Maruta A,Ishigatsubo Y,Kanamori H

    更新日期:2014-06-01 00:00:00

  • The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide.

    abstract::Thalidomide is thought to have anti-angiogenic and immunomodulatory properties, including suppression of tumor necrosis factor-alpha, effects on interleukins and interferons, down-regulation of some cell adhesion molecules, and changes in the proportion of lymphocyte subsets. It is unclear whether the clinical respons...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500078300

    authors: Strupp C,Germing U,Aivado M,Kündgen A,Fenk R,Hünerlitürkoglu A,Kobbe G,Haas R,Gattermann N

    更新日期:2005-07-01 00:00:00

  • Extensive analysis of the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cell compartment in a patient with tyrosine kinase inhibitor-resistant chronic myeloid leukemia.

    abstract::Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML). However, resistance is occasionally observed, mainly due to mutations within the BCR-ABL kinase domain. The T315I substitution confers complete resistance to all TKIs commonly used in clinical practice. To date, the ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.520774

    authors: Chomel JC,Sorel N,Bonnet ML,Bertrand A,Brizard F,Roy L,Guilhot F,Turhan AG

    更新日期:2010-11-01 00:00:00

  • Treatment of advanced Hodgkin's disease: EBVD versus intensive brief chemotherapy.

    abstract::We start a controlled clinical trial to assess efficacy and toxicity of EBVD (epirubicin, bleomycin, vinblastine and dacarbazine) with an intensive and brief program of seven drugs administered weekly for 12 weeks in previously untreated patients with advanced Hodgkin's disease. Two hundred and sixty four patients wer...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1080/1042819031000067729

    authors: Avilés A,Cleto S,Neri N,Huerta-Guzmán J,Talavera A,Castañeda C,González M

    更新日期:2003-08-01 00:00:00

  • Suicide gene-mediated modulation of graft-versus-host disease.

    abstract::The development of suicide genes and progress in retroviral gene transfer to T-cells open new perspectives for the treatment of graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation (BMT) for leukemia and lymphoma. Indeed, suicide genes that metabolize inactive prodrugs into compounds toxic for...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199909058474

    authors: Cohen JL,Boyer O,Thomas-Vaslin V,Klatzmann D

    更新日期:1999-08-01 00:00:00

  • Clinical implications of aberrant TSG101 transcripts in acute myeloblastic leukemia.

    abstract::Tsg101 is a mouse tumor suppressor gene whose homozygous deletion produces transformation of NIH3T3 cells and leads to metastases in nude mice. The human homologue of the gene, TSG101, is localized in chromosome 11p15.1-p15.2. Reduced TSG101 expression may cause the defect of the cell cycle checkpoint that leads to ge...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009148393

    authors: Lin SF,Lin PM,Liu TC,Chang JG,Sue YC,Chen TP

    更新日期:2000-02-01 00:00:00

  • Acute lymphoblastic leukemia in adult first manifested as severe aplastic anemia--role of molecular analysis in correct diagnosis.

    abstract::Aplastic anemia (AA) may sometimes precede the diagnosis of acute lymphoblastic leukemia (ALL) in children. Such presentation of ALL is externally rare in adults and until now only few such cases have been reported. We present a 40-year-old male with ALL common type, which developed 14 months after the diagnosis of se...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290021605

    authors: Robak T,Bartkowiak J,Urbańska-Rys H,Szmigielska-Kapłon A,Strzelecka B,Chojnowski K

    更新日期:2002-05-01 00:00:00

  • Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues.

    abstract::This report describes two cases of T-cell chronic lymphocytic leukemia (T-CLL) treated with purine nucleoside analogues. One patient had CD8+, CD3+ large granular lymphocytosis (LGL) producing transfusion-dependent anemia and was refractory to chemotherapy. Treatment with four cycles of fludarabine produced a clinical...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199409049659

    authors: Witzig TE,Weitz JJ,Lundberg JH,Tefferi A

    更新日期:1994-06-01 00:00:00

  • HIV-related non-Hodgkin's lymphoma: CHOP induction therapy and interferon-alpha-2b/zidovudine maintenance therapy.

    abstract::In a prospective multicenter study 68 out of 158 patients with HIV infection and malignant lymphoma were assigned to a risk-adapted induction therapy using the following algorithm: High-risk patients fulfilled 2 of 3 criteria: T4 lymphocytes <50/microL; WHO activity index 3 or 4; pre-existing AIDS-defining opportunist...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.3109/10428199809058386

    authors: Weiss R,Huhn D,Mitrou P,Nerl C,Schürmann D,Scheidegger C,Knauf W,Trenn G,Kronawitter U,Van Lunzen J,Arastéh K,Herbst H

    更新日期:1998-03-01 00:00:00

  • Cell cycle-independent down-regulation of BCL-2 protein expression in differentiating HL-60 cells.

    abstract::To understand the relationship between bcl-2 protein expression and the cell cycle during the processes of differentiation, we examined bcl-2 protein levels expressed during cell cycle phases in differentiating HL-60 human leukemia cells by using a two-color flow cytometric method. In exponentially proliferating HL-60...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009148859

    authors: Kumakura S,Ishikura H,Tsumura H,Nakashima A,Sato Y,Kobayashi S

    更新日期:2000-01-01 00:00:00

  • Epidemiology of myeloproliferative neoplasms in the United States.

    abstract::Myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) are three classic BCR ABL fusion gene-negative chronic myeloproliferative neoplasms (MPNs). Though rare, it is important to understand the burden of illness of these disorders for public health planning, healthcare insurers and pharmaceutica...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.813500

    authors: Mehta J,Wang H,Iqbal SU,Mesa R

    更新日期:2014-03-01 00:00:00

  • Augmented myeloablative conditioning with thiotepa in acute myeloid leukemia - improved outcomes with similar toxicity.

    abstract::Myeloablative doses of busulfan (Bu) with fludarabine (Flu) have reduced toxicity, however, limited by an increased relapse rate. We aimed to improve outcome of Flu-Bu regimen by augmentation with thiotepa (TT) (10 mg/kg). Eighty-nine patients with AML, 44 patients conditioned with Flu-Bu (group 1), and 45 patients au...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1510495

    authors: Sheth V,Nachmias B,Grisariu S,Avni B,Or R,Shapira M

    更新日期:2019-03-01 00:00:00

  • Cytokine receptor gene expression in peripheral blood mononuclear cells during graft-versus-host disease after allogeneic bone marrow transplantation.

    abstract::Interleukin-1 receptor type 1 (IL-1R), IL-2 receptor alpha subunit (IL-2R) and IL-6 receptor alpha subunit (IL-6R) mRNA expression in peripheral blood mononuclear cells (PBMC) in 17 patients who underwent allogeneic bone marrow transplantation (allo BMT) and 2 patients who underwent autologous transplantation were ana...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509107899

    authors: Tanaka J,Imamura M,Kasai M,Zhu X,Kobayashi S,Hashino S,Higa T,Sakurada K,Asaka M

    更新日期:1995-10-01 00:00:00

  • Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphoma.

    abstract::Low muscle mass (LMM) and low muscle density (LMD) are increasingly recognized as prognostic factors for survival in different malignancies. This study determined the association of LMM and LMD with survival in DLBCL (diffuse large B-cell lymphoma) patients. CT-based measurement of muscle was performed in 164 DLBCL pa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1737686

    authors: Rier HN,Kharagjitsing H,van Rosmalen J,van Vugt J,Westerweel PE,de Jongh E,Kock M,Levin MD

    更新日期:2020-07-01 00:00:00

  • Abnormalities of retinoblastoma gene expression in hematological malignancies.

    abstract::The human retinoblastoma gene product which is involved in cell cycle control and also acts as a transcriptional repressor of genes involved in growth control, is constitutively expressed as a phosphoprotein in normal hemopoietic cells. Abnormalities of the retinoblastoma gene expression leading to loss of protein exp...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199509064923

    authors: Zhu YM,Haynes AP,Keith FJ,Russell NH

    更新日期:1995-06-01 00:00:00

  • The presence of circulating clonal CD19+ cells in multiple myeloma.

    abstract::Multiple myeloma (MM) is a B-cell malignancy characterized by the expansion of mature plasma cells (PC) localized in the bone marrow (BM). Several studies have identified circulating clonotypic CD19+ cells at a differentiation stage preceding the PC. The level of circulating clonotypic CD19+ cells is highly variable b...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190109097764

    authors: Rasmussen T

    更新日期:2001-11-01 00:00:00

  • CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.

    abstract::We investigated CD25 expression in older (≥60 years) patients with new acute myelogenous leukemia treated with decitabine and plerixafor. Patients resistant to therapy or survival ≤1 year had significantly higher percentages of CD25pos myeloid blasts in baseline bone marrow. CD25pos patients had an increased odds of r...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1352089

    authors: Allan JN,Roboz GJ,Askin G,Ritchie E,Scandura J,Christos P,Hassane DC,Guzman ML

    更新日期:2018-04-01 00:00:00

  • Isolated myelosarcoma in children--update and review.

    abstract::Primary myelosarcomas, also called leukemia cutis, granulocytic sarcomas or chloromas, are rare extramedullary manifestations of acute myeloid leukemia (AML) which precede bone marrow involvement. Skin infiltration was the most frequent localization associated with a myelomonocytic differentiation. Although first remi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190290012056

    authors: Reinhardt D,Creutzig U

    更新日期:2002-03-01 00:00:00

  • Haploidentical hematopoietic stem cell transplantation for adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.

    abstract::To assess the efficacy of haploidentical hematopoietic stem cell transplantation (HSCT) in adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH), we retrospectively analyzed 30 cases that presented at our institution. At the time of HSCT, 20 patients (66.7%) had achieved a resp...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1330467

    authors: Li Z,Wang Y,Wang J,Zhang J,Wang Z

    更新日期:2018-01-01 00:00:00